Week In Review: Hutchison China MediTech (Chi-Med) To Raise $100 Million In US Offering Next Week

Hutchison China MediTech (Chi-Med) will raise $100 million by listing ADS shares on the NASDAQ exchange next week; Meinian Onehealth, a Shanghai provider of China medical exams, will acquire the remaining 72% of a rival, Ciming Health Checkup, for $415 million; two affiliated China investors, Lummy and China BioPharma Capital, contributed to a $60 million fundraising for Argos Therapeutics, a US cancer immunotherapy company; Haisco Pharma secured China rights to a novel treatment for chronic wounds developed by Microbion, a US-Canada biopharma; China is working to negotiate discounts of at least 50% on five expensive western drugs; Bristol-Myers Squibb stopped direct-to-doctor sales support activities in China; Roche was granted CFDA approval for its CINtec® PLUS Cytology test, which detects pre-cancerous cervical disease; BeiGene of Beijing was approved to start China clinical trials of a BTK inhibitor; and 3SBio of Shenyang was given a green light to begin China trials of a long-acting chemotherapy.